Searched for
ORGANON DRUG MAKER
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Stocks in news: RIL, IDFC First Bank, Paytm, Sun Pharma, Manappuram FinanceIndian markets faced pressure extending a corrective phase. Key companies like RIL, IDFC First Bank, and Paytm reported their financial res...
- Stocks in news: LIC, Maruti Suzuki, Sun Pharma, TCS, HULIndian markets extended their gains on Friday, with analysts predicting a steady recovery towards the 24,300-24,700 zone. Several prominent...
- Sun Pharmaceutical to adopt a 'disciplined' approach to M&A: Dilip ShanghviAsked about the strategic priorities in the US, he added: "Not only the US, but we have interest in selling innovative medicines globally.....
- Sun Pharma places non-binding offer for US-based Organon in its boldest global bet everSun Pharmaceutical Industries Ltd has submitted a non-binding offer to acquire US-based Organon for an all-cash deal, securing $10-14 billi...
- Sun Pharma looks to rise in US with $10 billion Organon buyIndia's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based Organon, a sp...
- Fosun taps big buyout funds for Gland PharmaBuyout firms Advent International, Baring Private Equity Asia (now owned by EQT), Bain Capital, Blackstone, Carlyle and KKR are among those...
- Zydus Cadila acquires six brands from Merck IndiaThe acquired brands Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range had clocked sales of Rs 840 million in 2015.
- Merck's Indian unit MSD may sell primary care drugs to focus on core brandsA sizeable part of the divestiture is from the primary care segment with a few Indian drug makers showing interest. Valuation is, however, ...
Load More
